LevWise · Antidote to reflex prescribing.Compare all antiseizure medicines →

Patient Information Leaflet

Print this leaflet and bring it to your next appointment.

What is this leaflet?

This leaflet is designed to help you have an informed conversation with your neurologist or GP about levetiracetam (Keppra). It summarises the key evidence and provides questions you may wish to ask. It is not medical advice — always discuss treatment decisions with your doctor.

6 Questions to Ask Your Neurologist

1

What type of epilepsy do I have — focal, generalised, or unknown? Does this affect which drug is best for me?

2

Is levetiracetam the most effective first-line option for my specific epilepsy type, given the SANAD II trial results?

3

What are the neuropsychiatric risks of levetiracetam, and how will we monitor for them?

4

Do I have any risk factors (psychiatric history, high dose, age) that make neuropsychiatric side effects more likely?

5

If this drug does not control my seizures, how will we determine whether my epilepsy is truly drug-resistant or whether a different drug choice might work?

6

Are there alternative antiepileptic drugs that might be better suited to my situation?

Warning Signs to Watch For

common

Increased irritability or aggression

10–20% of patients. Report to your doctor if it affects relationships or daily life.

common

Low mood or depression

13% of patients. Seek help promptly — do not wait for the next scheduled appointment.

urgent

Thoughts of self-harm or suicide

Seek emergency help immediately. All antiepileptic drugs carry a class warning for suicidality.

urgent

Rash with fever or swollen glands

May indicate DRESS — a rare but serious reaction. Stop the drug and seek emergency care.

common

Memory or concentration problems

Cognitive effects are reported. Discuss with your doctor if affecting work or daily activities.

urgent

Behavioural changes in children

Parents should monitor closely. Aggression, emotional lability, and regression have been reported.

What the Evidence Shows

32%
More likely to fail treatment vs lamotrigine
SANAD II, Lancet 2021
20–35%
Experience behavioural adverse events
Gunderson 2022
47%
Seizure-free with correct first drug choice
Kwan & Brodie, NEJM 2000

Important Disclaimer

This leaflet is for informational and educational purposes only. It does not constitute medical advice and should not be used to make treatment decisions without consulting a qualified healthcare professional. Never stop or change your medication without medical supervision — sudden changes to antiepileptic drugs can cause serious harm.

Email contact being updated

Our new contact details will appear here once they are ready. Email enquiries are temporarily unavailable.

Medical Disclaimer: This website is for informational and educational purposes only. It does not constitute medical advice and should not replace consultation with a qualified healthcare professional. Always discuss treatment decisions with your doctor.